Molecular genetics external quality assessment pilot scheme for kras analysis in metastatic colorectal cancer

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 11, 2011, Pages 777-783

  Deans, Zandra C ^a   Tull, Justyna ^b   Beighton, Gemma ^c   Abbs, Stephen ^d   Robinson, David O ^e,f   Butler, Rachel ^b  

^a INSTITUTE OF HUMAN GENETICS   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^c Source BioScience   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; COLORECTAL CANCER; GENE MUTATION; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; HYBRIDIZATION; LABORATORY TEST; MEDICAL ERROR; METASTASIS; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PYROSEQUENCING; QUALITY CONTROL; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EVALUATION STUDIES AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; MALE; MOLECULAR BIOLOGY; MUTATION; NEOPLASM METASTASIS; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS; QUALITY ASSURANCE, HEALTH CARE; RAS PROTEINS;

EID: 81755162834     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0239     Document Type: Article

References (11)

1. Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634.
2. Cross J (2008) DxS Ltd. Pharmacogenomics 9:463-467. (Pubitemid 351803928)
3. Di Fiore F, Blanchard F, Charbonnier F, et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166-1169. (Pubitemid 46625066)
4. Dufort S, Richard M-J, de Fraipont F (2009) Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumour tissues. Anal Biochem 391:166-168.
5. Edkins S, O'Meara S, Parker A, et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5:928-932.
6. Lievre A, Bachet JB, Boige V, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced co-lorectal cancer treated with cetuximab. J Clin Oncol 26:374-379. (Pubitemid 351171687)
7. Lievre A, Bachet JB, Le CD, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995.
8. Newton CR, Graham A, Heptinstall LE, et al. (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acid Res 17:2503-2516. (Pubitemid 19103235)
9. Ogino S, Kawasaki T, Brahmandam M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by pyr-osequencing. J Mol Diagn 7:413-421. (Pubitemid 41149657)
10. Ramsden SC, Deans Z, Robinson DO, et al. (2006) Monitoring standards for molecular genetic testing in the United Kingdom, The Netherlands, and Ireland. Genet Test 10:147-156. (Pubitemid 44849882)
11. van Krieken JHJM, Jung A, Kirchner T, et al. (2008) Virchows Arch 453:417-431.